Blood Cancer Study Shows New Drug Combo Beats Standard Treatment

A clinical trial found that a two-drug combination of ibrutinib and venetoclax outperformed traditional chemotherapy for certain blood cancers, with particular benefits for patients showing minimal residual disease. The finding could reshape treatment protocols and pharmaceutical market dynamics in oncology.

Originaltitel: Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study